EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 335 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July June 25, 2025 Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical... December 20, 2022 Load more HOT NEWS Atlantic rowing trio smash world record and raise thousands for cancer... Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... Active Surveillance for Low-Risk Prostate Cancer Continues to Rise
